BIOLINERX
Careers | Contact Us
search

Press Releases
April 17, 2013
BL-7040 met the primary efficacy endpoint of the study
BL-7040 was also shown to be safe and well tolerated 
April 10, 2013
Partial results expected in Q4 2013
Final results expected in H2 2014
March 20, 2013
Management call scheduled for Wednesday, March 20th, at 11:00 a.m. EDT
February 28, 2013
Preclinical data shows that EDP-14 significantly blocks allergic responses
February 26, 2013
Management to hold conference call at 10:00 a.m. EST
211-220  Out of  309 Previous
 1   2   3   4   5   6   7   8   9   10   11   12   13   14   15 
 16   17   18   19   20   21   22   23   24   25   26   27   28   29 
 30   31 
Next